Patents Assigned to Pharmacia & Upjohn Company
  • Publication number: 20030207866
    Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
    Type: Application
    Filed: April 15, 2003
    Publication date: November 6, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Stephen J. King
  • Patent number: 6642238
    Abstract: The present invention provides a compound of formula I which have potent activities against gram-positive and gram-negative bacteria.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: November 4, 2003
    Assignee: Pharmacia and Upjohn Company
    Inventor: Jackson B. Hester, Jr.
  • Patent number: 6642235
    Abstract: Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: November 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Patent number: 6641994
    Abstract: The invention provides methods to identify specific inhibitors of HPV E7 binding to CDK2 complex and methods to identify specific inhibitors of E7-induced CDK2 kinase activity. Specific inhibitors identified by the methods, compositions comprising the specific inhibitors, and methods of treatment using the compounds are also provided.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: November 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Christopher Fisher, Wanxia He
  • Patent number: 6638731
    Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A&bgr; processing is altered.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: October 28, 2003
    Assignee: Pharmacia and Upjohn Company
    Inventors: Mark E. Gurney, Adele M. Pauley, Jinhe Li
  • Patent number: 6632799
    Abstract: A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefor, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a pH of from 2.5-3.5 and a concentration of said doxorubicin of from 0.1 to 100 mg/ml.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: October 14, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Gaetano Gatti, Diego Oldani, Giuseppe Bottoni, Carlo Confalonier, Luciano Gambini, Roberto De Ponti
  • Patent number: 6632621
    Abstract: The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.
    Type: Grant
    Filed: November 24, 2000
    Date of Patent: October 14, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Timothy G. Geary, Teresa M. Kubiak, Martha J. Larsen
  • Patent number: 6630311
    Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: October 7, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Dennis E. Epps, Charles K. Marschke
  • Publication number: 20030180821
    Abstract: The present invention provides methods of identifying agents that bind gene products critical for the survival of microbes, preferably Staphylococcus microbes, including agents that interfere with the expression of such gene products and agents that interfere with the function of such gene products.
    Type: Application
    Filed: May 2, 2003
    Publication date: September 25, 2003
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Che-Shen C. Tomich, Cheryl L. Quinn, Staffan Arvidson, John E. Mott, Douglas W. Harris
  • Patent number: 6624159
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: September 23, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: David John Anderson, Gordon L. Bundy, Fred L. Ciske, David R. Graber, Michael J. Genin, Thomas M. Judge, Malcolm Wilson Moon, Mark E. Schnute, Joseph Walter Strohbach, Suvit Thaisrivongs, Atli Thorarensen, Steven Ronald Turner, Valerie A. Vaillancourt, Allison J. Wolf
  • Patent number: 6620810
    Abstract: The invention provides a compound of formula I: wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: September 16, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Atli Thorarensen
  • Patent number: 6613349
    Abstract: Disclosed is a method of treating a non-topical infection selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of an Oxazolidinone.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: September 2, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Charles W. Ford, Jeffrey L. Watts
  • Patent number: 6613944
    Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X2—CH2—C*H(OH)—CH2—NH—CO—RN  (VIIIA) and processes for production of pharmacologically useful oxazolidinones.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: September 2, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman
  • Publication number: 20030162750
    Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.
    Type: Application
    Filed: March 21, 2003
    Publication date: August 28, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mathew Cherian, Shireesh Prakash Apte
  • Patent number: 6610690
    Abstract: This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: August 26, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Patent number: 6608050
    Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: August 19, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mathew Cherian, Shireesh Prakash Apte
  • Patent number: 6608220
    Abstract: The present invention is a process for the conversion of bisnoralcohol to bisnoraldehyde (II), which is a known intermediate in the synthesis of progesterone.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: August 19, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Bradley D. Hewitt
  • Patent number: 6605609
    Abstract: The present invention provides a thizaine oxazolidinone useful as antimicrobial.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: August 12, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Michael Robert Barbachyn, Gary Edward Zurenko
  • Patent number: 6602868
    Abstract: The invention provides methods and use of heterocyclic amines, and phenylazacycloalkane compounds, and their pharmacologically acceptable salts for the treatment of Restless Legs Syndrome (RLS).
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: August 5, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Sylvia McBrinn, Richard Wayne Anderson
  • Patent number: 6599916
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: July 29, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Bruce N. Rogers, Vincent E. Groppi, Jr., David W. Piotrowski, Alice L. Bodnar, Eric Jon Jacobsen, Jeffrey W. Corbett